Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.We found that inhibiting MELK or ALK can effectively target specific breast cancer (BC) subtypes. These targeted therapies show promise for personalized treatment strategies in ERα-positive BC.
Area Of Science
- Oncology
- Molecular Biology
- Biochemistry
Background
- Breast cancer (BC) remains a significant global health challenge, with accurate subtyping crucial for effective treatment.
- Estrogen receptor alpha (ERα), progesterone receptor (PR), and HER2 expression are key factors in classifying BC subtypes.
- Current therapeutic strategies require refinement for optimal outcomes across diverse BC molecular profiles.
Purpose Of The Study
- To investigate the therapeutic potential of targeting specific kinases in ERα-positive breast cancer subtypes.
- To identify novel therapeutic vulnerabilities by combining bioinformatic and wet lab approaches.
- To explore synergistic effects of kinase inhibitors with established BC therapies.
Main Methods
- Utilized a combination of bioinformatic analysis, wet lab screening, signal transduction assays, and cell proliferation studies.
- Employed multiple breast cancer cell lines representing diverse subtypes.
- Investigated the effects of MELK and ALK inhibitors on ERα-positive BC cells and their response to hormonal and HER2-targeted therapies.
Main Results
- Enhanced sensitivity of ERα-positive BC cell lines to MELK and ALK inhibitors was observed, leading to ERα degradation and reduced proliferation.
- MELK inhibition suppressed ERα transcriptional activity and E2-induced gene expression in MCF-7 cells.
- Synergistic anti-proliferative effects were noted between MELK inhibition and tamoxifen, and between ALK inhibition and HER2 inhibitors in specific BC subtypes.
Conclusions
- MELK is a promising therapeutic target for ERα-positive/PR-positive/HER2-negative BC.
- ALK presents a potential therapeutic target for ERα-positive/PR-negative/HER2-positive BC.
- Kinase inhibitors offer a promising avenue for developing personalized and effective therapeutic strategies for diverse breast cancer subtypes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...